1
|
Alyamani N, Sargos P, Blanchard P, Supiot S, Ronchin P, Pommier P, Duberge T, Silva M, Hammoud Y, Hasbini A, Khalifa J, Gnep K, Scrase C, Saez J, Vieillevigne L, Christiaens M, Zilli T, Ribault H, Bossi A, Fizazi K, Andratschke N. OC-0609 Radiotherapy quality assurance of the PEACE-1 trial: Initial results of individual case reviews. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02631-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Benhmida S, Sun R, Gherga E, Hammoud Y, Rouvier J, Mauvais O, Bockel S, Louvrier A, Lebbad A, Bontemps P, Ortholan C, Bourhis J, Lestrade L, Sun XS. Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases. Cancer Radiother 2020; 24:812-819. [PMID: 33144061 DOI: 10.1016/j.canrad.2020.03.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2020] [Revised: 03/16/2020] [Accepted: 03/23/2020] [Indexed: 10/23/2022]
Abstract
PURPOSE To assess the efficacy and the tolerance of a split course hypofractionated (SCH) radiotherapy (RT) protocol in head and neck cancer (HNC) for eldery and/or unfit patients (pts). PATIENTS AND METHODS Pts with HNC treated by SCH-RT in two institutions were included retrospectively. The main SCH RT regimen was two courses of 30 grays (Gy)/10 fractions separated by 2-4 weeks, without any systemic therapy. RESULTS Between February 2012 and January 2019, 75 consecutive patients were analyzed. The median age was 80 years (range: 45.7-98.2) and 53 (70.7%) were men. Sixty-one (81.3%) pts had stage III/IV disease and 54 (72%) had at least two comorbidities. All of them were treated with intensity-modulated radiotherapy. Median follow-up was 10.6 months (range: 3.1-58.3). Local control at 12 and 24 months was 72.8% IC95%[62-85.5] and 51.7% IC95%[38.1-70.1] respectively. Progression free survival (PFS) at 12 and 24 months were 47.7% IC95%[37.4-60.8] and 41% IC95%[15-36.4] respectively, with a median of 11.5 months IC95%[8.9-17]. OS at 12 and 24 months were 60.4% IC95%[50-73.1] and 41% IC95%[30.6-54.9] respectively, with a median of 19.3 months IC95%[11.9-25.8]. Acute and late grade 3 or higher toxicities occurred for 6 (8%) and 3 (4%) pts. CONCLUSION The present SCH-RT regimen seems effective, well-tolerated and could represent an alternative to palliative strategies for pts deemed unfit for standard exclusive RT.
Collapse
Affiliation(s)
- S Benhmida
- Department of radiotherapy, CHU de Besancon, 2, boulevard Fleming, 25030 Besançon, France; Department of radiotherapy, Hopital Nord Franche-Comté de Montbéliard, site du Mittan, 1 rue Henri Becquerel, 25220 Montbéliard, France.
| | - R Sun
- Department of radiotherapy, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| | - E Gherga
- Department of radiotherapy, CHU de Besancon, 2, boulevard Fleming, 25030 Besançon, France; Department of radiotherapy, Hopital Nord Franche-Comté de Montbéliard, site du Mittan, 1 rue Henri Becquerel, 25220 Montbéliard, France
| | - Y Hammoud
- Department of radiotherapy, CHU de Besancon, 2, boulevard Fleming, 25030 Besançon, France; Department of radiotherapy, Hopital Nord Franche-Comté de Montbéliard, site du Mittan, 1 rue Henri Becquerel, 25220 Montbéliard, France
| | - J Rouvier
- Department of radiotherapy, Hopital Nord Franche-Comté de Montbéliard, site du Mittan, 1 rue Henri Becquerel, 25220 Montbéliard, France
| | - O Mauvais
- Department of head and neck surgery, CHU de Besançon, 2, boulevard Fleming, 25030 Besançon, France
| | - S Bockel
- Department of radiotherapy, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| | - A Louvrier
- Department of Maxillofacial Surgery and Stomatology, CHU de Besançon, 2, boulevard Fleming, 25030 Besançon, France
| | - A Lebbad
- Department of head and neck surgery, Hôpital Nord Franche-Comté, 100, route de Moval, Trevenans, France
| | - P Bontemps
- Department of radiotherapy, CHU de Besancon, 2, boulevard Fleming, 25030 Besançon, France; Department of radiotherapy, Hopital Nord Franche-Comté de Montbéliard, site du Mittan, 1 rue Henri Becquerel, 25220 Montbéliard, France
| | - C Ortholan
- Department of radiotherapy, Centre hospitalier Princesse-Grace, 98000 Monaco, Monaco
| | - J Bourhis
- Centre Hospitalier Universitaire Vaudois, Service de Radio-oncologie, 1005 Lausanne, Switzerland
| | - L Lestrade
- Department of radiotherapy, CHU de Besancon, 2, boulevard Fleming, 25030 Besançon, France; Department of radiotherapy, Hopital Nord Franche-Comté de Montbéliard, site du Mittan, 1 rue Henri Becquerel, 25220 Montbéliard, France
| | - X S Sun
- Department of radiotherapy, CHU de Besancon, 2, boulevard Fleming, 25030 Besançon, France; Department of radiotherapy, Hopital Nord Franche-Comté de Montbéliard, site du Mittan, 1 rue Henri Becquerel, 25220 Montbéliard, France
| |
Collapse
|
7
|
Shaw E, Stea B, Pinter T, Hammoud Y, Cagnoni PJ, Hackman J, Boyd A, Craig M, Marks J, Suh J. Pharmacokinetics (PK) of RSR13 (efaproxiral) predict survival in patients with brain metastases randomized to receive whole brain radiation therapy (WBRT) with or without RSR13 (REACH RT-009). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1561] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Shaw
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - B. Stea
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - T. Pinter
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - Y. Hammoud
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - P. J. Cagnoni
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - J. Hackman
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - A. Boyd
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - M. Craig
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - J. Marks
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| | - J. Suh
- Wake Forest University School of Medicine, Winston-Salem, NC; University of Arizona Health, Tucson, AZ; Petz Aladar Hospital of Gyor-Moson, Gyor, Hungary; Hopital de Montbéliard, Montbéliard, France; Allos Therapeutics, Inc, Westminster, CO; Cleveland Clinic, Cleveland, OH
| |
Collapse
|